About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 6042 record(s)
Req # A-2023-001527
As of December 15, 2023, there are now two liraglutide submissions which appear on the Generic Submissions Under Review (GSUR) List. Provide the name of the company who submitted the Abbreviated New Drug Submission (ANDS); and the year and month in which the ANDS was accepted for review.Organization: Health Canada
May 2024
Req # A-2023-001536
As part of its application to Health Canada for authorization to sell the COVID-19 lateral flow device with the Interim Order (IO) authorization Identification 327866, the manufacturer sent the federal government about 200 sample tests. Provide the report that the Health Canada team led by the Director General received from the National Microbiology Laboratory on the test's accuracy and considered as they evaluated the application, approving it on October 20, 2021.Organization: Health Canada
May 2024
Req # A-2023-001537
As part of its application to Health Canada for authorization to sell the three COVID-19 lateral flow devices with the Interim Order (IO) authorization Identifications 313054, 328889, and 333956, the manufacturer sent the federal government about 200 sample tests for each one. Provide the reports that the Health Canada team led by the Director General received from the National Microbiology Laboratory on the tests' accuracy andconsidered as they evaluated the applications, approving the three devices respectively in February, June and December 2021.Organization: Health Canada
May 2024
Req # A-2023-001572
Any security related training completed by Nadine Huggins, the Senior Assistant Deputy Minister (ADM) and Chief Security officer at Health Canada.Organization: Health Canada
May 2024
Req # A-2023-001628
All communications originating from atrazine registrants, or their agents or representatives including the triazine network to the Pest Management Regulatory Agency (PMRA) regarding the aquatic reference values for atrazine and all PMRA internal emails and memoranda discussing those communications. Time period is January 1, 2023 to March 28, 2024.Organization: Health Canada
May 2024
Req # A-2024-000044
Documents and records containing information regarding the mock-ups of every label to be used in connection with the Fourth Desmopressin Abbreviated New Drug Submission (ANDS) and mock-ups of the drug product’s packages, as described in the Food and Drug Regulations.Organization: Health Canada
May 2024
Req # A-2024-000045
The most recent Module 2.3: Quality Overall Summary (QOS) submitted by the sponsor for the Fourth Desmopressin Abbreviated New Drug Submission (ANDS).Organization: Health Canada
May 2024
Req # A-2024-000046
Any Canadian Reference Product Confirmation submitted by the sponsor of the Fourth Desmopressin Abbreviated New Drug Submission (ANDS).Organization: Health Canada
May 2024
Req # A-2024-000050
If the Fourth Desmopressin Abbreviated New Drug Submission (ANDS) has received, a Screening Acceptance Letter, a Notice of Deficiency (NOD), a Notice of Non-Compliance (NON), a NOD-Withdrawal (NODW), a NON-Withdrawal (NON-W), provide the month and year that the notice was issued; and provide a copy of the correspondence.Organization: Health Canada
May 2024
Req # A-2024-000051
The Abbreviated New Drug Submission (ANDS) cover letter of the company who submitted the Fourth Desmopressin ANDS.Organization: Health Canada
May 2024